REPL News and Press, Replimune Group Inc. From 11/05/23

2023-11-05 10:05:05 ET Summary Replimune's fiscal health and clinical progress are being closely watched, with upcoming combination data for its lead candidate RP1 seen as a critical juncture. The company's Q2 earnings showed increased expenditures and a widening net loss, raising...

WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating R...

Replimune Group Inc. (REPL) is expected to report $-0.8 for Q2 2024

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-10-06 15:00:00 ET More on the stock market The U.S. Government Shutdown: Not A Crisis SPY Madness: 'Magnificent Seven' Stocks Up An Average 95% YTD While The Average Stock Is Down More Shades Of 2007 Buy-rated dividend stocks for volatility and high rate...

2023-09-19 08:33:08 ET More on Replimune Group Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group Financial information for Replimune Group Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment ...

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most ...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-14 17:28:47 ET Summary Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. The cutaneous squamous cell carcinoma treatment mar...

2023-08-03 10:09:10 ET Replimune Group press release ( NASDAQ: REPL ): Q1 GAAP EPS of -$0.75. Cash Position: As of June 30, 2023, cash, cash equivalents and short-term investments were $539.1 million, as compared to $583.4 million as of March 31, 2...